Interview with Patrice Zagamé, CEO, Novartis France
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
As dermo-cosmetics inventors, Pierre Fabre Dermo Cosmetics innovates in skin care and hair care fields and solutions following a sacrosanct principle of beauty rooted in ethics.
Backed by a pharmaceutical laboratory, the key to our scientific excellence, Pierre Fabre designs dermo-cosmetic treatments according to the most rigorous criteria for efficacy and safety. At Pierre Farbe, we are focused on acquiring the most cutting-edge expertise and technology, particularly in natural substances, hydrotherapy in dermatology, biotechnologies, and sterile cosmetics.
Recommended by health care professionals, our dermo-cosmetic treatments are administered by staff trained in our beauty ethics approach, thus guaranteeing individually tailored solutions.
As specialists in dermatological therapy with Pierre Fabre Dermatology we are no. 1 in Europe and no. 2 globally on the dermo-cosmetics market, with sales of over €1 billion across 130 countries, and a portfolio of 10 complementary brands.
Pierre Fabre is committed to developing our brands in all parts of the world. Each brand in our portfolio has its own DNA and is positioned to target a different type skin types and needs. Our brands are based on natural active ingredients: thermal spring water for Avène, Rhealba® Oat for A-Derma, plant extracts for Klorane and Elancyl, essential oils and plant extracts for René Furterer. Our dermo-cosmetics products are developed, clinically tested and manufactured according to the standards set out by the pharmaceutical industry.
Contact
Pierre Fabre Dermo-Cosmetics
Les Cauquillous
81506 Lavaur Cedex
+33 149 10 81 68
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the…
We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has…
Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away…
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective…
Baxter is approaching 40 years in France, what have been the major milestones of the group during this period and what is the importance of France to the group? During…
Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
Nordic Pharma has been established in the French market since 2002 as one of its first steps towards internationalization. What have been the main milestones and achievements of Nordic in…
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Octapharma was founded in 1983 and entered decisively in the French market in 1999, when it acquired a plasma facility in Lingolsheim, Alsace. Since then, what have been the main…
As the market leader in the French pre-wholesale market, Depolado had a quite impressive market share growth in the previous 3 years, now being responsible for a quarter of the…
See our Cookie Privacy Policy Here
